Substituted Cyclic Modulators of Protein Phosphatase 2A
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective chemical modulators of Protein Phosphatase 2A (PP2A) to treat, prevent, or ameliorate PP2A-associated pathologies such as cancer, diabetes, autoimmune diseases, and other conditions where PP2A is implicated.
Innovation Solution
Development of specific compounds of formula (I) and their pharmaceutical compositions, which can be administered to subjects in need, targeting PP2A-related diseases by modulating PP2A activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemical modulators of PP2A are developed to treat PP2A-associated pathologies, then therapeutic efficacy is improved, but the complexity of drug development and clinical translation increases
Solution Approach 1:
The patent segments the complex PP2A modulation challenge into manageable compound series with distinct structural features (e.g., compounds of formula I, II, and III with specific substituent patterns). This segmentation allows systematic optimization of individual compound properties while maintaining overall therapeutic efficacy, reducing the complexity of developing a single comprehensive solution.
Solution Approach 2:
The patent applies parameter changes by systematically varying chemical substituents (R1, R2, R3, R4, R5, R6, R7, R8, R9, X1-X7, Y, Z) in the compound structures to optimize PP2A modulation activity. This approach enables fine-tuning of pharmacological properties while maintaining the core therapeutic mechanism, thereby improving efficacy without proportionally increasing development complexity.
2Manufacturing precision
If specific compound structures are designed to modulate PP2A activity, then selectivity and efficacy are improved, but the difficulty of synthesis and manufacturing increases
Solution Approach 1:
The patent divides the complex multi-substituent compound structures into modular building blocks (core structures with variable substituents). This modular approach allows independent optimization and synthesis of each component, which can then be assembled through standardized coupling reactions, thereby maintaining high selectivity while reducing overall synthesis difficulty.
Solution Approach 2:
The patent designs universal core structures (e.g., the central scaffold in formulas I, II, and III) that can accommodate multiple different substituent patterns. This universality allows a single synthetic route to produce multiple active compounds with different selectivity profiles, reducing the need for entirely separate synthesis pathways for each compound variant.
3Adaptability or versatility
If compounds are developed for multiple PP2A-related diseases, then versatility of treatment is improved, but the complexity of clinical trials and regulatory approval increases
Solution Approach 1:
The patent develops compound series with broad PP2A modulation activity that can address multiple disease indications (cancer, diabetes, autoimmune diseases, neurodegenerative diseases, etc.). This multi-functionality allows a single compound or compound class to be evaluated across multiple disease models, reducing the total number of separate drug development programs needed while maintaining versatility.
Solution Approach 2:
The patent employs dynamic substituent variations in the compound structures that can be adjusted to optimize activity for specific disease indications. This dynamic approach allows the same core compound to be adapted for different therapeutic areas through systematic substituent modification, thereby achieving versatility without requiring entirely separate drug development pathways for each indication.
Data Source
AI summary
The present disclosure relates in part to chemical modulators of protein phosphatase 2A (PP2A). The compounds of the present disclosure are useful in treating, preventing, and/or ameliorating cancer, diabetes, autoimmune disease, solid organ transplant rejection, graft vs host disease, chronic obstructive pulmonary disease (COPD), non-alcoholic fatty liver disease, abdominal aortic aneurysm, chronic liver disease, heart failure, neurodegenerative disease, and cardiac hypertrophy.